|
The Devices
Teaching, Research, Service
U.S. Trials FDA Approves
Hershey, Pa. --- The Food and Drug Administration has approved the first series of U.S. clinical
trials for a new kind of heart assist device, called the Arrow LionHeartTM , developed by Penn
State researchers in conjunction with Arrow International, Inc. of Reading, Pa.
The first heart assist device powered via wireless electric transmission to reach clinical
trial, the Arrow LionHeartTM
The Arrow LionHeartTM is not an artificial heart. It is a "heart helper" or left ventricle assist
system for patients suffering from severe heart failure who are not eligible for a natural heart
transplant. The patient's natural failing heart is left in place and the assist device is connected to it
to boost circulation. Once the system is implanted in a patient, no wires, tubes or other
connections protrude through the skin.
Under the direction of Walter E. Pae, Jr., M.D., Penn State professor of surgery and Arrow, clinical trials have been proceeding in Europe since October 1999. The Arrow LionHeartTM has been implanted in 10 patients. The longest survivor has
had the assist device for nearly a year. There have been no device failures.
The new heart assist device is based on an approach originated by Dr. William S. Pierce,
who founded the Penn State artificial organs program, coupled with the latest in electronics and
biomaterials technology. Penn State members of the design team include Dr. Gerson Rosenberg,
professor of bioengineering, Dr. Alan Snyder, associate professor of surgery, and Dr. W. J. Weiss,
assistant professor of surgery, at the College of Medicine in Hershey as well as materials, energy
and fluid flow researchers at Penn State's University Park campus.
Pumping is achieved in the heart assist device when a metal plate presses on a plastic
blood sac, forcing the blood out of the sac. In the Arrow LionHeart, the metal plate is driven by a
new miniature electric motor and controller that responds to a patients' changing needs during
exercise and resting, for example.
The Arrow LionHeartTM has both internal rechargeable batteries, which remain in the body,
and an external battery pack fitted with a unique power delivery coupling. The external source,
two battery packs worn on a belt, powers the motor via a transformer coil worn on the outside of
the chest. When the external transformer coil is positioned over an internal transformer coil
connected to the motor, it induces a current. The internal and external coils coupled wirelessly
through the chest wall maintain the pump's operation. Should the patient want to be untethered
from the external battery packs, for example, to take a shower, the internal batteries can supply
power needs for a minimum of 20 minutes at a time. In addition, the wireless operation
significantly lowers the potential for infection. (For more details, go to www.arrowintl.com
Dr. Pae notes that about 4 million patients in the U.S. are victims of heart failure and
nearly 400,000 new cases are diagnosed each year. Of these patients, only about 2,800 receive
heart transplants. "The LionHeart is intended to help this much larger population that is ineligible
for transplant and for whom medical therapy has failed," he adds.
Contacts:
Mindy Kelchner
|
![]()
A'ndrea Messer for problems with this web site.
|